Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April July May June August September October November December
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

UFS works closely with employees in the post-Reitz settlement process
2013-05-20

20 May 2013

In the light of an article in IOL News on 18 and 19 May 2013 and in Sunday Independent and Sunday Tribune on 19 May 2013 in which it is alleged that the University of the Free State (UFS) has failed to honour its commitment to the five Reitz employees we are pleased to report on the ongoing process and progress made with respect to their employment.

The university remained consistently true to the settlement agreement and High Court order of 2011 and cannot apologise for complying with the law. It was therefore impossible for us to talk to our colleagues directly until last week when we had a breakthrough meeting, which was cleared by the Human Rights Commission (HRC), and matters were resolved.

The UFS continues to work closely and now directly with the five employees to ensure that their rights as employees remain the highest priority in the post-settlement process.
 
All but one of the conditions of the Reitz settlement (own business) has already been met; however, we are in the process of providing training and support for the establishment of an independent business led by the employees.

After some delays, and frustration on all sides, we have found the right training provider for them and are satisfied that the process remains on track. The business office (furnished) has been allocated at the South Campus in Bloemfontein.

Already in late 2012 the Chair of the HRC expressed his satisfaction with the commitments made by the university to the process. By 30 June 2013 this outstanding commitment to establish an independent company with trained employees would also have been met in full.

Beyond the settlement agreement, the UFS has also committed to providing free education and training to the children of the employees so that their next generation of families emerge as strong, independent, well-trained and productive members of society. The child of one of the colleagues is in fact finishing Grade 12 this year and we are in discussion about possible studies at the UFS. This is our pledge and commitment as a university.

This final step in the post-Reitz settlement is being led by Dr Choice Makhetha, Vice-Rector of the University of the Free State.

 

Issued by: Lacea Loader
Director Strategic Communication
Tel: +27 (0) 51 401 2584 / +27 (0) 83 645 2454
E-mail: news@ufs.ac.za
Fax: +27 (0) 51 444 6393
Web: www.ufs.ac.za

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept